Article Information
History
- October 21, 2020.
Article Versions
- Version 1 (October 20, 2020 - 07:36).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Lei Shi1,2,*,
- Hai Huang3,4,*,
- Xuechun Lu2,5,*,
- Xiaoyan Yan6,*,
- Xiaojing Jiang7,
- Ruonan Xu1,
- Siyu Wang1,
- Chao Zhang1,2,
- Xin Yuan1,2,
- Zhe Xu1,2,
- Lei Huang1,2,
- Jun-Liang Fu1,2,
- Yuanyuan Li1,
- Yu Zhang8,9,
- Weiqi Yao9,10,
- Tianyi Liu2,11,
- Jinwen Song1,2,
- Liangliang Sun4,12,
- Fan Yang13,
- Xin Zhang2,14,
- Bo Zhang7,
- Ming Shi1,
- Fanping Meng1,
- Yanning Song1,
- Yongpei Yu6,
- Jiqiu Wen2,
- Qi Li2,
- Qing Mao2,
- Markus Maeurer16,17,
- Alimuddin Zumla18,
- Chen Yao6,#,
- Wei-Fen Xie4,15,# and
- Fu-Sheng Wang1,2,#
- 1Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China
- 2Wuhan Huoshenshan Hospital, Wuhan, China
- 3Department of Respiratory, Changzheng Hospital, Second Military Medical University, Shanghai, China
- 4Optical Valley Branch of Maternal and Child Hospital of Hubei Province, Wuhan, China
- 5Department of Hematology, Second Medical Center of Chinese PLA General Hospital, Beijing, China
- 6Peking University Clinical Research Institute, Peking University First Hospital, Beijing, China
- 7Department of Infectious Disease, General Hospital of Central Theater Command, Wuhan, China
- 8VCANBIO Cell & Gene Engineering Corp., Ltd. Tianjin, China
- 9National Industrial Base for Stem Cell Engineering Products, Tianjin, China
- 10Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 11Key Laboratory of Cancer Center, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
- 12Department of Endocrinology and Metabolism, Changzheng Hospital, Second Military Medical University, Shanghai, China
- 13Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 14Nursing Department, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
- 15Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, China
- 16Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal
- 17I Med Clinic, University of Mainz, Mainz, Germany
- 18Center for Clinical Microbiology, Division of Infection and Immunity, University College London, and UCL Hospitals NIHR Biomedical Research Centre, London, UK
- ↵#Correspondence to: Prof. Fu-Sheng Wang, Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, No.100 Western 4th Ring Road, Beijing 100039, China. fswang302{at}163.com, Prof. Wei-Fen Xie, Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai, 200003, China. weifenxie{at}medmail.com.cn, Prof. Chen Yao, Peking University Clinical Research Institute, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China yaochen{at}hsc.pku.edu.cn
↵* Drs. Lei Shi, Hai Huang, Xuechun Lu and Xiaoyan Yan contributed equally to this article.
Posted October 21, 2020.
Treatment with human umbilical cord-derived mesenchymal stem cells for COVID-19 patients with lung damage: a randomised, double-blind, placebo-controlled phase 2 trial
